Intellia Therapeutics (NTLA) Payables (2016 - 2025)
Historic Payables for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to $13.3 million.
- Intellia Therapeutics' Payables rose 87.49% to $13.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.3 million, marking a year-over-year increase of 87.49%. This contributed to the annual value of $14.6 million for FY2024, which is 9577.29% up from last year.
- According to the latest figures from Q3 2025, Intellia Therapeutics' Payables is $13.3 million, which was up 87.49% from $9.8 million recorded in Q2 2025.
- Intellia Therapeutics' Payables' 5-year high stood at $18.8 million during Q2 2024, with a 5-year trough of $3.6 million in Q3 2023.
- Its 5-year average for Payables is $9.7 million, with a median of $9.7 million in 2021.
- As far as peak fluctuations go, Intellia Therapeutics' Payables soared by 9781428.57% in 2021, and later plummeted by 4790.6% in 2025.
- Intellia Therapeutics' Payables (Quarter) stood at $9.7 million in 2021, then tumbled by 46.61% to $5.2 million in 2022, then skyrocketed by 44.59% to $7.5 million in 2023, then soared by 95.77% to $14.6 million in 2024, then decreased by 9.11% to $13.3 million in 2025.
- Its Payables stands at $13.3 million for Q3 2025, versus $9.8 million for Q2 2025 and $12.4 million for Q1 2025.